Prosecution Insights
Last updated: April 19, 2026
Application No. 18/063,531

Systems and Methods for Live Cell Imaging

Non-Final OA §102§112
Filed
Dec 08, 2022
Examiner
NGUYEN, HENRY H
Art Unit
1758
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Emory University
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
166 granted / 258 resolved
-0.7% vs TC avg
Strong +38% interview lift
Without
With
+37.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
94 currently pending
Career history
352
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
42.2%
+2.2% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
29.7%
-10.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 258 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-10, in the reply filed on 09/07/2025 is acknowledged. Claims 11-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/07/2025. Information Disclosure Statement No IDS was filed for this application. The applicant and/or the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application (see MPEP §§ 704.10 - 704.13). In response to this requirement, please provide a copy of any related and pertinent information, such as non-patent literature, published application(s) or patent(s) (U.S. or foreign), that was used to assist in the drafting of this application. The applicant is reminded of the duty to disclose information that is material to patentability (see 37 CFR § 1.56). A complete reply to the instant Office action must include a complete reply to this requirement. The time period for reply to this requirement coincides with the time period for reply to the instant Office action. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3 and 8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 3, claim 3 recites the limitation "the at least a portion of the UV light" in line 2. There is insufficient antecedent basis for this limitation in the claim. Note that claim 2 establishes “at least a portion of the UV light” while claim 3 is dependent on claim 1. Regarding claim 8, claim 8 recites “of claim further comprising”. The dependency of claim 8 is unclear. For examination purposes, claim 8 is being interpreted as being dependent upon claim 1. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-10 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Gentalen (US 20170176386 A1). Regarding claim 1, Gentalen teaches a live cell imaging system (Figs. 1-3) comprising: a substrate (Figs. 2-3 interpreted as the middle layer 206 and bottom layer 210 of microfluidic device 212 and 302; paragraph [0068] teaches the microfluidic device of Fig. 3 is simplified and the channel structure is described in Figs. 1-2) made, at least in part, out of polydimethylsiloxane (PDMS) (paragraph [0040] teaches the substrate of the microfluidic device is made of PDMS), having a cavity (Fig. 2, viewable enrichment zone 207) configured to hold a sample comprising one or more live cells (Fig. 2 and paragraph [0064] teaches channel comprising a viewable enrichment zone 207, which is structurally capable of holding live cells; paragraph [0071] teaches loading cells into the device); a UV light source (Fig. 3, light source 306; paragraph [0117], “UV light source”) configured to direct UV light to the sample (Fig. 3 and paragraph [0117] teaches the UV light source 306 directing UV light to the device 302 comprising a sample); and a UV camera (Fig. 3, detector 308; paragraph [0117], “CCD camera… ThorLabs, 340UV-GE”, which is a UV camera) configured to take a UV image of the sample (paragraph [0117] teaches a ThorLabs, 340UV-GE CCD camera, which is structurally configured to take a UV image of a sample; paragraphs [0027],[0073]-[0076] teaches imaging the microfluidic device). Regarding claim 2, Gentalen further teaches wherein the UV light source (Fig. 3, light source 306; paragraph [0117], “UV light source”) is positioned such that at least a portion of the UV light is transmitted through the substrate (Fig. 3 shows at least a portion of the UV light is transmitted through the substrate of microfluidic device 302; paragraphs [0068] and [0115] teaches light passing through the channel of the device). Regarding claim 3, Gentalen further teaches wherein the UV light source (Fig. 3, light source 306; paragraph [0117], “UV light source”) is positioned such that the at least a portion of the UV light is transmitted through the substrate proximate the cavity (Fig. 3 shows at least a portion of the UV light is transmitted through the cavity of the substrate, i.e. proximate, of microfluidic device 302; paragraphs [0068] and [0115] teaches light passing through the channel of the device). Regarding claim 4, Gentalen further teaches wherein the cavity of the substrate is made, at least in part, of PDMS (paragraph [0040] teaches the substrate of the microfluidic device is made of PDMS). Regarding claim 5, Gentalen further teaches wherein the cavity of the substrate is made entirely of PDMS (paragraph [0040] teaches the substrate of the microfluidic device is made of PDMS, therefore, the substrate of the viewable enrichment zone 207 of Fig. 2 is made of PDMS). Regarding claim 6, Gentalen further teaches the live cell imaging system of claim 1 further comprising: a cover (Fig. 2, top layer 202) made, at least in part, out of polydimethylsiloxane (PDMS) (paragraph [0040] teaches the substrate of the microfluidic device is made of PDMS, therefore, the substrate, which includes the top layer 202 of Fig. 2 is made of PDMS), positioned above the cavity (Fig. 2 teach top layer 202 is above the viewable enrichment zone 207). Regarding claim 7, Gentalen further teaches wherein the cover encloses the cavity (Fig. 2 teach top layer 202 encloses the viewable enrichment zone 207). Regarding claim 8, Gentalen further teaches the live cell imaging system of claim 1 further comprising: an inlet (Fig. 2 and paragraphs [0064],[0067], inlet tube 209) configured to introduce the sample to the cavity (interpreted as a functional limitation, see MPEP 2114; paragraph [0118] teaches loading samples into the device via the inlet); and an outlet (Fig. 2 and paragraphs [0064],[0067], outlet tube 209) configured to remove the sample from the cavity (interpreted as a functional limitation, see MPEP 2114; paragraph [0118] teaches removing samples out of the device through the outlet). Regarding claim 9, Gentalen further teaches wherein the UV light has a wavelength between 200 nm and 400 nm (paragraph [0117] teaches a UV light source, LED, qphotonics, UVTOP280, which has a wavelength between 200-400 nm, e.g. at least the wavelength of 280 nm; paragraph [0062] teaches a UV range of interest of 200-300 nm). Regarding claim 10, Gentalen further teaches wherein the cavity has an optical density of less than 4 for UV light having a wavelength from 200nm to 400nm (Fig. 3 and paragraphs [0068]-[0069] teach the cavity or channel is a transparent channel region 304 used for optical detection and monitoring by allowing light to pass through the region; paragraph [0062] teaches a layer of the device is transparent, such as 100% transparent, i.e. optical density of 0, to light spectrum of interest such as 200-900 nm; paragraph [0117] teaches a UV light source and UV camera; therefore, it is inherent that the cavity has an optical density of less than 4 for a wavelength from 200-400 nm in order for the desired UV light to be transmitted through the microfluidic device to the detector as shown in Fig. 3). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Bransky et al. (US 20120035061 A1) teaches a live cell imaging system (Figs. 1-2) comprising: a substrate (Fig. 1, base surface 156 of cartridge 100) made, at least in part, out of polydimethylsiloxane (PDMS) (paragraph [0141]), having a cavity configured to hold a sample comprising one or more live cells (Fig. 1A, microchannel 102, which is capable of holding cells); a UV light source (Figs. 2A-2B, illumination source 202 or LED 302 ) configured to direct UV light to the sample (paragraphs [0173]-[0174] teach the light is UV radiation); and a UV camera (Figs. 2A-2B, camera 208; paragraph [0174] teaches a camera sensitive to UV) configured to take a UV image of the sample (paragraph [0174] teaches a camera sensitive to UV). Any inquiry concerning this communication or earlier communications from the examiner should be directed to HENRY H NGUYEN whose telephone number is (571)272-2338. The examiner can normally be reached M-F 7:30A-5:00P. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maris Kessel can be reached at (571) 270-7698. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HENRY H NGUYEN/Primary Examiner, Art Unit 1758
Read full office action

Prosecution Timeline

Dec 08, 2022
Application Filed
Oct 01, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12558689
VASCULAR DEVELOPMENT MONITORING SYSTEMS AND USES THEREOF
2y 5m to grant Granted Feb 24, 2026
Patent 12545874
SHORTFALL QUANTITY LIQUID CONTAINER
2y 5m to grant Granted Feb 10, 2026
Patent 12546733
CELL EVALUATION DEVICE
2y 5m to grant Granted Feb 10, 2026
Patent 12540347
METHOD TO DETECT AND ENUMERATE MICROORGANISMS
2y 5m to grant Granted Feb 03, 2026
Patent 12529631
DEVICE FOR STAINING 3D BIOPSY TISSUE
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+37.7%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 258 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month